Pfizer, Inc. (PFE) Holdings Trimmed by First Capital Advisors Group LLC.
First Capital Advisors Group LLC. trimmed its position in Pfizer, Inc. (NYSE:PFE) by 6.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,461 shares of the biopharmaceutical company’s stock after selling 1,858 shares during the period. First Capital Advisors Group LLC.’s holdings in Pfizer were worth $956,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also recently made changes to their positions in PFE. Shine Investment Advisory Services Inc. acquired a new stake in Pfizer in the second quarter valued at approximately $102,000. D. Scott Neal Inc. boosted its stake in Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 504 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC purchased a new position in shares of Pfizer in the first quarter worth $121,000. Cascade Investment Advisors Inc. raised its holdings in shares of Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 2,200 shares during the last quarter. Finally, Perennial Advisors LLC raised its holdings in shares of Pfizer by 7.9% in the second quarter. Perennial Advisors LLC now owns 5,132 shares of the biopharmaceutical company’s stock worth $172,000 after buying an additional 376 shares during the last quarter. Institutional investors own 69.10% of the company’s stock.
Shares of Pfizer, Inc. (NYSE:PFE) opened at $35.18 on Friday. The company has a market cap of $209,816.89, a price-to-earnings ratio of 14.08, a P/E/G ratio of 2.49 and a beta of 1.01. The company has a current ratio of 1.34, a quick ratio of 1.06 and a debt-to-equity ratio of 0.58. Pfizer, Inc. has a 52-week low of $30.51 and a 52-week high of $36.78.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.67%. The business had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. During the same quarter last year, the business earned $0.61 earnings per share. The company’s revenue for the quarter was up .9% compared to the same quarter last year. equities analysts expect that Pfizer, Inc. will post 2.59 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be given a $0.32 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 annualized dividend and a dividend yield of 3.64%. Pfizer’s dividend payout ratio (DPR) is 79.01%.
A number of research analysts have issued reports on PFE shares. Cowen and Company set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, August 14th. Jefferies Group LLC set a $35.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a report on Thursday, August 24th. Berenberg Bank reaffirmed a “hold” rating and issued a $36.00 price target (down previously from $39.00) on shares of Pfizer in a report on Tuesday, August 15th. Deutsche Bank AG set a $38.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, October 11th. Finally, Goldman Sachs Group, Inc. (The) set a $36.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a report on Wednesday, November 1st. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $38.48.
In other news, insider Alexander R. Mackenzie sold 7,350 shares of Pfizer stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total value of $249,900.00. Following the sale, the insider now owns 132,124 shares in the company, valued at $4,492,216. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Laurie J. Olson sold 8,064 shares of Pfizer stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $32.70, for a total transaction of $263,692.80. Following the completion of the sale, the insider now owns 74,506 shares in the company, valued at approximately $2,436,346.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 374,621 shares of company stock worth $12,796,098. Company insiders own 0.06% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.